Epidemiology of HPV 16 and Cervical Cancer in Finland and the Potential Impact of Vaccination: Mathematical Modelling Analyses

BACKGROUND: Candidate human papillomavirus (HPV) vaccines have demonstrated almost 90%-100% efficacy in preventing persistent, type-specific HPV infection over 18 mo in clinical trials. If these vaccines go on to demonstrate prevention of precancerous lesions in phase III clinical trials, they will...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Barnabas, Ruanne V, Laukkanen, Päivi, Koskela, Pentti, Kontula, Osmo, Lehtinen, Matti, Garnett, Geoff P
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Public Library of Science 2006
Gaiak:
Research Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC1434486/
https://ncbi.nlm.nih.gov/pubmed/16573364
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pmed.0030138
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak